Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1454-1463

  Ma, Christopher ^a   Huang, Vivian ^a   Fedorak, Darryl K ^a   Kroeker, Karen I ^a   Dieleman, Levinus A ^a   Halloran, Brendan P ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adalimumab; Crohn's disease; Dose escalation; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; METHOTREXATE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; AMBULATORY CARE; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG TOLERANCE; MAINTENANCE CHEMOTHERAPY; RETREATMENT; TIME;

ADULT; AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; MALE; METHOTREXATE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927786526     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.05.007     Document Type: Article

References (35)

1. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
3. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
4. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
5. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
6. Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13:1093-1099.
7. Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
8. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
9. Swoger J.M., Loftus E.V., Tremaine W.J., Faubion W.A., Pardi D.S., Kane S.V., et al. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis 2010, 16:1912-1921.
10. Danese S., Fiorino G., Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy. Aliment Pharmacol Ther 2011, 34:1-10.
11. Katz L., Gisbert J.P., Manoogian B., Lin K., Steenholdt C., Mantzaris G.J., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18:2026-2033.
12. Ma C., Panaccione R., Heitman S.J., Devlin S.M., Ghosh S., Kaplan G.G. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009, 30:977-986.
13. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
14. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
15. Lichtenstein G.R., Diamond R.H., Wagner C.L., Fasanmade A.A., Olson A.D., Marano C.W., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
16. Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
17. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
18. Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
19. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
20. Dignass A., Eliakim R., Magro F., Maaser C., Chowers Y., Geboes K., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohn's Colitis 2012, 6:965-990.
21. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
22. Hommes D.W., van de Heisteeg B.H., van der Spek M., Bartelsman J.F.W.M., van Deventer S.J.H., et al. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002, 8:81-86.
23. Rudolph S.J., Weinberg D.I., McCabe R.P. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008, 53:1033-1041.
24. Panaccione R., Loftus E.V., Binion D., McHugh K., Alam S., Chen N., et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 2011, 25:419-425.
25. Lichtiger S., Binion D.G., Wolf D.C., Present D.H., Bensimon A.G., Wu E., et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010, 32:1228-1239.
26. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., Ippoliti A., Dubinsky M.C., Birt J., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005, 100:75-79.
27. Peyrin-Biroulet L., Laclotte C., Bigard M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007, 25:675-680.
28. Ho G.T., Smith L., Aitken S., Lee H.M., Ting T., Fennell J., et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008, 27:308-315.
29. Chaparro M., Panes J., Garcia V., Manosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol 2011, 45:113-118.
30. Swaminath A., Ullman T., Rosen M., Mayer L., Lichtiger S., Abreus M.T. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment Pharmacol Ther 2009, 29:273-278.
31. Baert F., Glorieus E., Reenaers C., D'Haens G., Peeters H., Franchimont D., et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohn's Colitis 2013, 7:154-160.
32. Lee L.Y., Sanderson J.D., Irving P.M. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012, 24:1078-1085.
33. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
34. Bultman E., de Haar C., van Liere-Baron A., Verhoog H., West R.L., Kulpers E.J., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012, 35:335-341.
35. Fidder H.H., Singendonk M.M., van der Have M., Oldenburg B., van Oijen M.G.H. Low rates of adherence for tumor necrosis factor-alpha inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol 2013, 19:4344-4350.